SGLT2 inhibitors in biopsy-proven MASH patients with diabetes: Systematic review and meta-analysis (abstract interpretation)

A single-arm meta-analysis of diabetic patients with biopsy-proven MASH found SGLT2 inhibitors were associated with improvements in multiple liver, metabolic and histologic markers versus baseline, but the evidence is limited and should be interpreted cautiously [1].

Study type: Systematic Review,Journal Article,Meta-Analysis,Review (classification: Clinical guideline/high-quality systematic review) Published: Journal of diabetes and its complications, 2026-12-16 Source: PubMed public abstract

A single-arm meta-analysis of diabetic patients with biopsy-proven MASH found SGLT2 inhibitors were associated with improvements in multiple liver, metabolic and histologic markers versus baseline, but the evidence is limited and should be interpreted cautiously [1].

Why this study is worth attention

Why this study was done

Metabolic dysfunction–associated steatohepatitis (MASH, formerly called NASH) is the inflammatory and progressive stage of metabolic dysfunction–associated steatotic liver disease, and it increases the risk of cirrhosis, hepatocellular carcinoma and other extrahepatic complications. SGLT2 inhibitors have been investigated repeatedly in metabolic liver disease, but data specifically in diabetic patients with MASH confirmed by liver biopsy are limited; therefore the authors pooled relevant studies to estimate effects on liver biochemistry, imaging and histologic markers [1].

What the study actually found

Main results (based on the abstract)

• This was a single-arm random-effects meta-analysis including 7 trials with a total of 110 participants, assessing changes after SGLT2 inhibitor treatment compared with baseline [1].
• Liver-related measures: liver enzymes and controlled attenuation parameter (CAP) improved compared with baseline, with CAP standardized mean change ratio (SMCR) = -0.56 (95% CI -0.75 to -0.36) [1]; liver stiffness measurement (LSM) SMCR = -0.58 (95% CI -1.03 to -0.14) [1].
• Histology (liver biopsy): NAFLD Activity Score (NAS) SMCR = -1.18 (95% CI -2.29 to -0.06); the authors reported trends toward improvement in steatosis, ballooning and fibrosis (the abstract did not provide full item-by-item data) [1].
• Metabolic and cardiovascular risk markers: waist circumference SMCR -0.33 (95% CI -0.49 to -0.17); serum ferritin and systolic blood pressure also decreased versus baseline (abstract reports P < 0.05) [1].
• Heterogeneity (between-study variation) affected outcomes differently: heterogeneity was minimal to low for liver enzymes, CAP, weight and glycemic markers; higher heterogeneity was seen for LSM, triglycerides and some histologic outcomes. Regarding safety, the authors noted SGLT2 inhibitors were well tolerated in the included studies [1].

Possible implications for CKD, dialysis or transplant patients

What this means (interpretation points)

• Observed associations: among these diabetic participants with biopsy-proven MASH, use of SGLT2 inhibitors was associated with improvements in multiple liver imaging, laboratory and some histologic markers compared with their own baseline [1].
• What has relatively stronger evidence: the reported effect sizes suggest marker improvement in the short-to-medium term, but these results come from single-arm analyses with small sample sizes and cannot be taken as definitive proof of efficacy or as replacing established treatment principles.
• Practical reminder: these data should not be used to decide for an individual patient to stop, switch, or change drug dosages; nor should they be considered proof that this is standard therapy. Clinical decisions should rely on randomized controlled trials, guidelines and clinician judgment.

Limitations of current research

Study limitations

• This was a single-arm meta-analysis comparing post-treatment values to baseline, lacking more large randomized controlled trial direct-comparison evidence, so it is difficult to exclude confounding by time, other comorbidity treatments, or regression to the mean.
• Some outcomes showed high between-study heterogeneity, indicating inconsistent effects across trials and requiring cautious interpretation.
• Sample size was relatively small (7 trials, total 110 participants), limiting generalizability.
• This article was written based on the PubMed public abstract; the full text was not reviewed.
• The abstract did not provide all individual histologic detail or long-term clinical endpoints (such as cirrhosis progression, hepatocellular carcinoma, or mortality), so long-term benefits or rare adverse event risks cannot be evaluated.

Conclusions that remain uncertain

Unproven or still-to-be-studied questions

• Whether SGLT2 inhibitors reduce long-term clinical endpoints (for example, cirrhosis, hepatocellular carcinoma, liver-related mortality) is not established.
• Effects and safety of SGLT2 inhibitors in non-diabetic patients or in MASLD/MASH patients not confirmed by biopsy are outside the scope of this analysis and cannot be directly extrapolated.
• Comparative effects among different SGLT2 agents, dosing regimens, and treatment durations were not clearly addressed.
• Because the evidence consists of single-arm studies, causal relationships cannot be established and other confounding factors cannot be excluded; randomized controlled trials are needed for confirmation [1].

Questions to discuss with your clinical team

• Does this study mean I should start or stop SGLT2 inhibitors?
• Will SGLT2 inhibitors improve my long-term liver fibrosis outcomes?
• If I am not diabetic, do these results apply to me?
• Were the reported improvements versus placebo or only versus the patients' own baseline?
• What important safety issues or adverse effects should I be aware of when using SGLT2 inhibitors?
• What types of future studies would provide more definitive evidence?

How to read this study (our interpretation)

This section was written by the Beyond CKD editor — a kidney-transplant recipient with a health-management background, not a physician — using only the PubMed abstract. We have not read the full paper, and no clinician has reviewed this text. It is meant to help you understand the numbers, not to advise treatment.

What the study asked

There is a fair amount of research on SGLT2 inhibitors in fatty liver (MASLD), but very little in biopsy-confirmed steatohepatitis (MASH). This meta-analysis gathered 7 trials with 110 patients who had diabetes and biopsy-proven MASH and looked at liver markers and histology after treatment.

How to read the results

The key point: this is a single-arm meta-analysis — before-versus-after, with no control group. Effects are reported as standardised mean change (SMCR): liver-fat index CAP −0.56 (95% CI −0.75 to −0.36), liver stiffness LSM −0.58 (−1.03 to −0.14), biopsy NAFLD activity score −1.18 (−2.29 to −0.06; the upper bound is very close to zero), waist circumference −0.33; liver enzymes, steatosis, ballooning, fibrosis, ferritin and systolic blood pressure also improved. SMCR is measured in standard-deviation units — around 0.5 is a medium effect, above 1 is large — and cannot be converted directly into “so many kPa of stiffness”. Without controls, weight loss, better glucose control and lifestyle change could all have contributed, so the improvement cannot be attributed to the drug alone.

Limitations

Only 110 people across 7 trials and no randomised comparison. Heterogeneity was substantial for liver stiffness, triglycerides and histology. All participants had diabetes, so results do not extend to MASH without diabetes. The abstract gives no follow-up duration or specific drugs.

What it means for readers and people with kidney disease

If you have type 2 diabetes and steatohepatitis and already take an SGLT2 inhibitor (for your kidneys or heart, say), this is an early signal that it may also help the liver — but the evidence is low-certainty and the authors themselves urge caution. It is not, on its own, a reason to start the drug for fatty liver; dedicated MASH therapies (see our summary of the EASL guidance) have their own selection criteria.

How to check further

Ask your doctor: Has my fatty liver progressed to steatohepatitis or fibrosis? Among my current diabetes and kidney medicines, is there already something that may benefit the liver?

Original abstract: PubMed 42914763 (https://pubmed.ncbi.nlm.nih.gov/42914763/). Interpretation last updated 2026-11-06.

References

[1] Abdel Monem MS, Kamel AM, Abbassi MM, Sabry NA. SGLT2 inhibitors in diabetic biopsy proven MASH patients: A systematic review and meta-analysis.. Journal of diabetes and its complications. 2026. DOI: 10.1016/j.jdiacomp.2026.109437. PMID: 42914763.

Medical disclaimer: This article is for general health education and information only. It does not constitute individual medical diagnosis, treatment advice, or a doctor–patient relationship. Medical research is continually updated, and study findings have their own scope and limitations. Every patient's condition, laboratory values, medications and treatment needs differ. Do not stop or adjust medication doses, change your diet or fluid intake, or alter dialysis or transplant treatment based on this article alone. For any medical questions, please consult your nephrologist or another qualified healthcare professional.

Article created: 2026-11-01 | Original study published: 2026-12-16 | Last checked: 2026-11-01 (source metadata cross-checked with PubMed)